Cardio-deleterious implications of declining premenopausal ovarian reserve

Sexuality, Reproduction and Menopause

Volumn 7, Issue 3, 2009, Pages

  Pal, Lubna ^a   Hailpern, Susan M ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b LIPOSCIENCE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN;

AGING; ARTICLE; BONE DENSITY; BONE TURNOVER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; EARLY MENOPAUSE; FOLLITROPIN BLOOD LEVEL; HEART PROTECTION; HUMAN; OSTEOPOROSIS; OVARIAN RESERVE; OVARY FUNCTION; PREMENOPAUSE; PRIORITY JOURNAL; REPRODUCTION;

EID: 78649711933     PISSN: 15462501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Kannel WB, Hjortland MC, McNamara PM, et al. Menopause and risk of cardiovascular disease: the Framingham Study. Ann Intern Med. 1978;85:447-452.
2. Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril. 2001;76:874-878.
3. Rosano GM, Maffei S, Andreassi MG, et al. Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women. J Cardiovasc Med (Hagerstown). 2009;10:85-92.
4. Harman SM, Brinton EA, Cedars M, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric. 2005;8:3-12.
5. Jacobsen BK, Heuch I, Kvåle G. Age at natural menopause and all-cause mortality: a 37-year follow-up of 19,731 Norwegian women. Am J Epidemiol. 2003;157:923-929.
6. Banks E, Canfell K. Invited commentary: Hormone therapy risks and benefits-The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis. Am J Epidemiol. 2009;170:24-28.
7. Treolar AE. Menstrual cyclicity and the perimenopause. Maturitas. 1981;3:49-64.
8. Broekmans FJ, Kwee J, Hendriks DJ, et al. A systematic re- view of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12:685-718.
9. Farhi J, Homburg R, Ferber A, et al. Non-response to ovar- ian stimulation in normogonadotrophic, normogonadal women: a clinical sign of impending onset of ovarian failure pre-empting the rise in basal follicle stimulating hor- mone levels. Hum Reprod. 1997;12:241-243.
10. de Boer EJ, den Tonkelaar I, te Velde ER, et al; OMEGA- project group. A low number of retrieved oocytes at in vi- tro fertilization treatment is predictive of early meno- pause. Fertil Steril. 2002;77:978-985.
11. Chu MC, Rath KM, Huie J, et al. Elevated basal FSH in nor- mal cycling women is associated with unfavorable lipid levels and increased cardiovascular risk. Hum Reprod. 2003;18:1570-1573.
12. Woldringh GH, Frunt MH, Kremer JA, et al. Decreased ovarian reserve relates to pre-eclampsia in IVF/ICSI preg- nancies. Hum Reprod. 2006;21:2948-2954.
13. Miller PB, Soules MR. Correlation of reproductive aging with function in selected organ systems. Fertil Steril. 1997;68:443-448.
14. Pal L, Bevilacqua K, Zeitlian G, et al. Implications of di- minished ovarian reserve (DOR) extend well beyond re- productive concerns. Menopause. 2008;15:1086-1094.
15. Sun L, Peng Y, Sharrow AC, et al. FSH directly regulates bone mass. Cell. 2006;125:247-260.
16. Pal L, Zhang K, Zeitlian G, et al. Characterizing the repro- ductive hormone milieu in infertile women with dimin- ished ovarian reserve. Fertil Steril. 2008 Dec 17. (Epub ahead of print).
17. Pal L, Hailpern S, Santoro N. Cardiodeleterious implica- tions of declining ovarian reserve in premenopausal years: Analysis of NHANES (1999-2002) data. In: The En- docrine Society 90th Annual Meeting; June 2008; San Francisco, CA.